Skip Navigation
Photo of Robert Andtbacka

Robert Andtbacka Chief Medical Officer

Robert is an internationally recognized clinical expert and seasoned biopharma executive with more than 20 years of experience spanning therapeutic research and development, academic leadership, and company-building. He is widely published in his field, with over 80 peer-reviewed publications, 150 abstracts, and 4 book chapters.

Before joining Repertoire, Robert served as Chief Medical Officer at HiFiBiO Therapeutics, where he led the clinical and strategic development of the company’s immuno-oncology and autoimmune disease pipelines. Prior to that, he was Chief Medical Officer at Seven and Eight Biopharmaceuticals, where he directed the development of novel immunotherapies, oncolytic viruses, and antibody drug conjugates, and played a key role in the acquisition of clinical assets by Eikon Therapeutics.

Earlier in his career, Robert held academic and clinical leadership roles at the Huntsman Cancer Institute, University of Utah, where he was a tenured professor of surgical oncology, Co-Director of the Melanoma and Cutaneous Oncology Program, and Director of the Melanoma Clinical Research Program. He also served as Chief Medical Officer of Vestan Medical Imaging, overseeing preclinical and clinical development of imaging agents and companion devices.

Robert earned his MD, CM from McGill University, where he also completed his residency in General Surgery. He went on to complete a fellowship in Surgical Oncology at the University of Texas MD Anderson Cancer Center. He is a board-certified surgeon, a Fellow of the American College of Surgeons (FACS), and a Fellow of the Royal College of Surgeons of Canada (FRCSC).